(Q48893820)

16 February 2018

title

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. (English)

1 reference

16 February 2018

0 references

S Leveille

1

1 reference

16 February 2018

S Samuel

series ordinal

2

1 reference

16 February 2018

M-L Goulet

series ordinal

3

1 reference

16 February 2018

J Hiscott

series ordinal

4

1 reference

16 February 2018

publication date

11 March 2011

1 reference

16 February 2018

published in

Cancer Gene Therapy

1 reference

16 February 2018

volume

18

1 reference

16 February 2018

issue

6

1 reference

16 February 2018

page(s)

435-443

1 reference

16 February 2018

https://scigraph.springernature.com/pub.10.1038/cgt.2011.14

exact match

0 references

cites work

Oncolytic viruses: an approved product on the horizon?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

VSV-tumor selective replication and protein translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Vesicular stomatitis virus: re-inventing the bullet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Suicide genes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Recombinant vesicular stomatitis viruses from DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

Oncolytic viruses move forward in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.14

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2011.14

1 reference

16 February 2018

PubMed ID

21394109

1 reference

16 February 2018